2Simon K, Rotter K, Zalewska M, et al. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B. Med Sci Monit,2000,6:971-975.
3Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology,2001,34: 1021-1026.
4Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology, 1998,114: 988-995.
5Heijtink RA, Janssen HL, Hop WC. Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication. J Med Virol,2001,63:217-219.
6Perrilloa RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdral for the treatment of chronic hepatitis B. N Engl J Med, 1990,323:295-301.
7Nafa S, Ahmed S, Tavan D, et al. Early detectioin of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology, 2000,32:1078-1088.
8Wolters LM, Van-Nunen AB, Niesters HG, et al. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients. Scand J Gastroenterol,2000,232: Suppl 74-78.
9Puchhanuner-Stocki E, Mandl CW, Kletzmayr J, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis, 2000,181: 2063-2066.
10Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviralresistant human hepatitis B virus mutations in the polymerase region.Hepatology,2001,33: 751-757.
6Leoni S, Piscaglia F, Righini R, et al. Management of Small hepato- cellular carcinoma[J]. Acta Gastroenterol Belg, 2006,69 ( 2 ) : 230- 235.
7Luo ZB, Li LJ, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China o- ver a 20-year period[J]. Int J Infect Dis,2012(16) :82-88.
8Darwish Murad S, Kim WR, de Groen PC, et al. Can the model for end-stage liver disease be used to predict the prog- nosis in patients with Budd-Chiari syndrome [ J ]. Liver Transpl, 2007,13 (6) : 867-874.
9Malinchoe M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular in- trahepatic portosystemic shunts [ J ]. Hepatology, 2000, 31 (4) :864-871.
10Hache C, Villeneuve JR. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis[J]. Expert Opin Phar macother, 2011,7 : 1835-1843.
